Insulet earnings date
Insulet (GOV) Q3 2026 Earnings Report
DE:GOV Q3 2026 EPS Results
- Actual EPS
- EUR 1.78
- Consensus EPS
- EUR 1.42
- Beat/Miss
- Beat by +EUR 0.36
- One Year Ago EPS
- EUR 1.11
DE:GOV Q3 2026 Revenue Results
- Actual Revenue
- EUR 753.88M
- Expected Revenue
- EUR 745.50M
- Beat/Miss
- Beat by +EUR 8.39M
- YoY Revenue Growth
- +19.21%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- Before Open
- Conference Call
- Wednesday, November 4, 2026
Insulet's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Insulet reported nearly 20% third-quarter revenue growth, more than 20% customer-base growth, record gross margin, substantial operating-margin expansion, and 60% adjusted EPS growth. The company also raised its confidence in the high end of 2026 guidance, advanced multiple product and commercial initiatives, and announced increased share repurchase capacity. The main concerns were softer new customer starts, type 2 retention challenges, expected competitive share pressure, and a more conservative 2027 outlook with meaningful moderation in international growth.
For full year 2026, Insulet expects constant currency revenue growth of 21% to 22% for total company and 21.5% to 22.5% for total Omnipod, with foreign exchange expected to positively contribute approximately a 100-basis-point to Omnipod and total company growth; US Omnipod revenue growth is expected at 17.5% to 18.5%, international Omnipod revenue growth at 32% to 33%, and fourth quarter total company, total Omnipod, US Omnipod, and international Omnipod revenue growth at 13.5% to 17%, 13% to 16.5%, 10% to 13.5%, and 21% to 24%, respectively, with foreign exchange expected to be a headwind of approximately 50 basis points to international growth. Insulet expects approximately 150 basis points of adjusted operating margin expansion, net interest and other expense of $40 million to $45 million, a non-GAAP tax rate of 20% to 20.5%, approximately 70 million shares outstanding, adjusted EPS growth of more than 30%, and free cash flow of approximately $275 million in 2026. For 2027, the company expects total company growth to be modestly below the mid teens framework, plans to guide toward the lower end of the prior 9% to 14% framework for the US, and expects international growth to moderate meaningfully from 2026; formal guidance is expected in February.
- Strong Third-Quarter Revenue GrowthThird-quarter revenue was $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis. U.S. revenue grew 14.7%, while international revenue grew 31.7% reported and 33% in constant currency.
- Customer Base Increased More Than 20%The global customer base grew more than 20% year over year, with U.S. customer growth in the high teens. The installed base provides a recurring revenue foundation, while consumption patterns remained consistent with customer-base growth.
- Record Gross Margin and Expanded Operating MarginAdjusted gross margin reached a record 74.2%, expanding 200 basis points year over year. Adjusted operating margin was 22%, up 490 basis points, reflecting revenue growth, gross-margin expansion, operating leverage, and lower annual employee bonus accruals.
- Adjusted EPS Growth Outpaced Revenue GrowthThird-quarter adjusted EPS was $1.99, up 60% from $1.24 in the prior-year period, significantly outpacing revenue growth.
- Full-Year 2026 Revenue Outlook Narrowed to the High EndThe company narrowed its full-year outlook to the high end of its prior range and now expects 2026 constant-currency revenue growth of 21% to 22% for the total company and 21.5% to 22.5% for total Omnipod. Foreign exchange is expected to positively contribute approximately 100 basis points to total-company and Omnipod growth.
- Raised 2026 Profitability and Cash-Flow ExpectationsInsulet now expects approximately 150 basis points of adjusted operating-margin expansion in 2026, adjusted EPS growth of more than 30%, and approximately $275 million of free cash flow. The company expects net interest and other expense of $40 million to $45 million and a non-GAAP tax rate of 20% to 20.5%.
- International Business Delivered Strong MomentumInternational Omnipod revenue grew 33% in constant currency in the third quarter. Full-year 2026 international Omnipod growth is expected at 32% to 33% in constant currency, supported by strong year-to-date performance, continued market momentum, and a price-mix benefit that contributed high single digit growth.
- Commercial Capabilities ExpandedInsulet completed its second U.S. sales-force expansion in two years, increasing its footprint by nearly 25% in the latest phase. Field representatives completed a new four-month certification program, and the company launched its first new U.S. CRM platform in more than a decade.
- Type 2 Diabetes Action Plan ProgressedThe company implemented changes to sampling governance, added clinical retention specialists to customer care, and incorporated customer retention into sales-force compensation. Type 2 retention rates improved modestly in the third quarter, with management stating that the impact of these initiatives is expected to build over time.
- Omnipod Discover Reached Full U.S. Market ReleaseOmnipod Discover completed its full U.S. market release in October. The platform had been adopted by more than 35,000 people with diabetes and 5,000 clinicians as of the call. During the limited release, the company reported stronger retention, increased time in range, and 75% of users reporting greater confidence in managing their diabetes.
- Omnipod 5 Algorithm Enhancement Rolled OutA new Omnipod 5 algorithm enhancement reached full U.S. retail availability. It adds a 100 milligrams per deciliter target and reduces automated-delivery restriction alarms; real-world evidence showed more time in range without a meaningful increase in lows.
- Broader Sensor Integration and Product PipelineFreestyle Libre 3+ integration was extended to 10 new markets, while the U.S. iOS platform limited market release is expected in the fourth quarter and would provide access to 450,000 MDI users. The company is also advancing Omnipod 6 and a fully closed-loop system for people with type 2 diabetes.
- Omnipod 6 Progress and Clinical PerformanceOmnipod 6 adapts to bolusing behavior with 40% fewer boluses. Adults and adolescents with type 1 diabetes spent 76% of time in range in reported data. Insulet submitted the second and final 510(k) and continues to expect a 2027 launch.
- Fully Closed-Loop Type 2 Program AdvancedInsulet completed enrollment in the EVOLVE pivotal study and continues to target a 510(k) submission in 2027 and a planned launch in 2028. In the EVOLVE 3 feasibility study, adults with type 2 diabetes using both a GLP-1 and CGM saw additional time-in-range benefits and had no user-initiated boluses.
- Expanded Access and Prescriber ReachNearly 34,000 U.S. health care providers were prescribing Omnipod, up more than 20% year over year. Insulet launched in Spain, finalized one of three U.S. PBM contracts for 2027, and expects to complete the remaining two in the next few weeks. The company reported more than 98% coverage and strong Medicaid, Medicare, and preferred coverage.
- Manufacturing Scale and Liquidity Supported Capital ReturnInsulet cited manufacturing capacity across Acton, Malaysia, and planned Costa Rica operations, with the ability to produce tens of millions of pods annually. The company ended the quarter with $584 million in cash and investments and $750 million available under its revolver. The board approved a $1 billion increase in share-repurchase authorization, with $400 million planned for repurchases in the fourth quarter.
- Continued Category Leadership and Market ExpansionManagement stated that Insulet has driven two-thirds of global AID market growth over the past five years and that Omnipod captures the majority of new AID customers. More than 85% of Omnipod new customer starts come from MDI, and Omnipod was identified as the number-one AID choice among providers and people with diabetes in the company's survey across six countries.
DE:GOV Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | 1.58- | 1.39 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 1.421.78 | 1.11 | 60.48% (+0.67) | |
| Aug 05, 2026 | 2026 (Q2) | 1.311.49 | 1.05 | 41.88% (+0.44) | |
| May 06, 2026 | 2026 (Q1) | 1.071.27 | 0.91 | 39.22% (+0.36) | |
| Feb 18, 2026 | 2025 (Q4) | 1.311.39 | 1.03 | 34.78% (+0.36) | |
| Nov 06, 2025 | 2025 (Q3) | 1.021.11 | 0.81 | 37.78% (+0.30) | |
| Aug 07, 2025 | 2025 (Q2) | 0.821.05 | 0.49 | 112.73% (+0.56) | |
| May 08, 2025 | 2025 (Q1) | 0.710.91 | 0.65 | 39.73% (+0.26) | |
| Feb 20, 2025 | 2024 (Q4) | 0.901.03 | 1.29 | -20.14% (-0.26) | |
| Nov 07, 2024 | 2024 (Q3) | 0.700.81 | 0.66 | 21.62% (+0.14) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


